Institutional members access full text with Ovid®

Share this article on:

Therapeutic effect of aqueous extract from Ecliptae herba on bone metabolism of ovariectomized rats

Zhang, Zhi-Guo PhD1; Bai, Dong PhD1; Liu, Mei-Jie PhD1; Li, Yan MS1; Pan, Jing-Hua BS1; Liu, Hong BS1; Wang, Wen-Lai MS1; Xiang, Li-Hua BS1; Xiao, Gary Guishan PhD2; Ju, Da-Hong PhD1

doi: 10.1097/GME.0b013e318265e7dd
Original Articles

Objective: Ecliptae herba (EH) has long been used in China to strengthen bones. Accumulating evidence indicates that EH may have antiosteoporotic effects. The aim of this study was to evaluate the effects of aqueous EH extract (EHE) on rats that had osteoporosis-like features induced by ovariectomy, using aqueous Fructus Ligustri Lucidi extract as positive control agent.

Methods: Three-month-old female rats that underwent ovariectomy were treated with EHE (1.4 g/kg per day). After 12 weeks, bone mineral density and bone histomorphometric indices of tibiae were measured. Protein and messenger RNA expressions of osteoprotegerin and receptor activator of nuclear factor κ-B ligand (RANKL) in tibiae were evaluated by immunohistochemistry and in situ hybridization. In addition, serum concentrations of osteocalcin, interleukin-1β, interleukin-6 (IL-6), calcitonin (CT), and parathyroid hormone were determined by enzyme-linked immunosorbent assay.

Results: EHE treatment prevented body weight gain and loss of uterine wet weight in ovariectomized rats. It remarkably increased bone mass in ovariectomized rats compared with ovariectomized controls. EHE treatment significantly down-regulated RANKL expression in tibiae from ovariectomized rats compared with controls; however, it had no significant effect on osteoprotegerin expression. In addition, EHE treatment significantly reduced serum IL-6 levels and remarkably increased CT levels but had no effect on parathyroid hormone.

Conclusions: EHE increases bone mass in ovariectomized rats by inhibiting bone loss: down-regulated RANKL expression in tibiae and IL-6 level in serum, and up-regulated CT level in serum. This suggests that EHE may be developed as an alternative therapeutic agent for osteoporosis induced by postmenopause.

From the 1Institute of Basic Theory, China Academy of Chinese Medical Sciences, Beijing, China; and 2Functional Genomics and Proteomics Laboratory, Osteoporosis Research Center, Creighton University Medical Center, Omaha, NE.

Received April 3, 2012; revised and accepted June 21, 2012.

Funding/support: This work was supported by the Special Social Commonweal Research Programs of China (2005DIB1J168), the National Natural Science Foundation of China (81102680), and the China Postdoctoral Science Foundation (20100470524).

Financial disclosure/conflicts of interest: None reported.

Address correspondence to: Da-Hong Ju, PhD, Institute of Basic Theory, China Academy of Chinese Medical Sciences, No. 16 Nanxiaojie, Dongzhimennei, Beijing 100700, China. E-mail: judahong@sohu.com; or Gary Guishan Xiao, PhD, Functional Genomics and Proteomics Laboratory, Osteoporosis Research Center, Creighton University Medical Center, 601 North 30th Street, Suite 6730, Omaha, NE 68131. E-mail: gxiao@creighton.edu

© 2013 by The North American Menopause Society.